Article Archive: Damien Conover, CFA

Title Collection Author Date
U.S. Elections Add Uncertainty to Healthcare Stocks Stock Analyst Update Damien Conover, CFA 11/09/16
Pfizer Looks Undervalued Despite Pipeline Setback Stock Analyst Update Damien Conover, CFA 10/31/16
Weak Third Quarter but Eli Lilly Looks Well Positioned Stock Analyst Update Damien Conover, CFA 10/25/16
Merck Posts Solid Third Quarter Stock Analyst Update Damien Conover, CFA 10/25/16
Competition Is Concerning for Johnson & Johnson Stock Analyst Update Damien Conover, CFA 10/18/16
Bristol-Myers Squibb's Lost Ground Stock Analyst Update Damien Conover, CFA 10/10/16
Healthcare: We See Value in the Drug and Biotech Industries Quarter-End Insights Damien Conover, CFA 10/05/16
Drug Pricing Power Transcends Politics Stock Strategist Damien Conover, CFA 09/09/16
Clinton Drug Plan No Threat to Innovators Stock Analyst Update Damien Conover, CFA 09/02/16
Pfizer Expands Cancer Platform With High-Priced Medivation Acquisition Commentary Damien Conover, CFA 08/22/16
No Pain, Potential for Lots of Gain Stock Strategist Industry Reports Damien Conover, CFA 08/19/16
Merck Could Gain from Bristol's Poor Drug Trial Results Stock Analyst Update Damien Conover, CFA 08/05/16
Lilly's Growth Prospects Are Improving Stock Strategist Damien Conover, CFA 08/01/16
Where Pharma Firms Still Have Pricing Power US Videos Damien Conover, CFA 08/01/16
What the Market Misses About Eli Lilly US Videos Damien Conover, CFA 07/27/16
Drug Group Lifts J&J; Shares Still Overvalued Commentary Damien Conover, CFA 07/19/16
Healthcare: Stock Selection Increasingly Important Quarter-End Insights Damien Conover, CFA 06/30/16
Recent Drug Launches Buoy Bayer's Growth Stock Strategist Damien Conover, CFA 04/27/16
Steady Growth at J&J Reinforces Wide Moat, But Shares Overpriced Commentary Damien Conover, CFA 04/19/16
Allergan Still Undervalued as Likelihood of Pfizer Deal Fades Commentary Damien Conover, CFA 04/05/16
Healthcare: Drug Reform Worries Are Overblown Stock Strategist Damien Conover, CFA 03/29/16
Healthcare Slump Is a Buying Opportunity US Videos Damien Conover, CFA 02/17/16
Pfizer's Pipeline Productivity Is Improving Stock Strategist Damien Conover, CFA 02/05/16
Pfizer Looks Undervalued Commentary Damien Conover, CFA 02/02/16
Steady Growth Supports J&J’s Wide Moat Commentary Damien Conover, CFA 01/26/16
Healthcare: Even After Uptick, Some Great Values Remain Quarter-End Insights Damien Conover, CFA 12/30/15
3 Underappreciated Pharma Stocks US Videos Damien Conover, CFA 11/28/15
Allergan Buy Strengthens Undervalued Pfizer's Moat Commentary Damien Conover, CFA 11/23/15
Pfizer's Fair Value Gets a Booster Commentary Damien Conover, CFA 10/27/15
Merck Looks Undervalued Commentary Damien Conover, CFA 10/27/15
Lilly's Moat Still Intact After Halting Heart Drug Study Commentary Damien Conover, CFA 10/12/15
Health Care: Recent Pullback Opens Door to More Compelling Valuations Quarter-End Insights Damien Conover, CFA 09/30/15
Merck's New Drugs Offset Patent Losses Stock Strategist Damien Conover, CFA 09/25/15
2 High-Quality Health-Care Bargains US Videos Damien Conover, CFA 07/31/15
J&J’s Drug Pipeline Not Strong Enough to Accelerate Growth Commentary Damien Conover, CFA 07/14/15
Health Care: A Few Stocks Still Offer Upside Quarter-End Insights Damien Conover, CFA 07/01/15
This Pharma Firm Passes the Test Stock Strategist Damien Conover, CFA 04/29/15
Market Undervalues Merck’s Pipeline Commentary Damien Conover, CFA 04/28/15
Caution: Slowing Growth Ahead for J&J Commentary Damien Conover, CFA 04/14/15
Health Care: 3 Picks in a More Expensive Sector Quarter-End Insights Damien Conover, CFA 04/01/15
Pfizer's Acquisition of Hospira Strengthens Its Moat at a Fair Price Commentary Damien Conover, CFA 02/05/15
Pfizer May Go Shopping for Growth Commentary Damien Conover, CFA 01/27/15
J&J Faces Headwinds in 2015 Commentary Damien Conover, CFA 01/20/15
Health Care: A Strong Run, but Some Stocks Still Look Undervalued Quarter-End Insights Damien Conover, CFA 12/31/14
Sanofi Shakes Off Patent Losses Stock Strategist Damien Conover, CFA 11/24/14
Led by Drug Sales, J&J Posts Solid Third Quarter Commentary Damien Conover, CFA 10/14/14
Health Care: Some Healthy Bargains Still Remain Quarter-End Insights Damien Conover, CFA 10/01/14
Blockbusters Differentiate Novartis Stock Strategist Damien Conover, CFA 09/05/14
J&J's Strong 2Q Led by Pharmaceuticals Commentary Damien Conover, CFA 07/15/14
Stock-Picking Increasingly Critical in Health Care Quarter-End Insights Damien Conover, CFA 06/28/14